1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Embecta Corp.

Embecta Corp.

EMBC
Embecta Corp.US flagNASDAQ Global Select
5.65
USD
-0.14
- -
335.20MMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.46
19.04
20.44
19.8
19.58
19.51
18.53
17.32
Basic EPS, GAAP
7.58
7.5
7.28
3.92
1.23
1.36
1.64
1.49
Free Cash Flow per Basic Share
8.81
8.75
7.96
7.22
1.18
0.62
3.29
2.96
Dividend per Share
- -
- -
- -
0.15
0.6
0.6
0.6
0.46
Book Value per Share
- -
10.04
10.43
-15.62
-14.33
-12.8
-11.13
-10.81
Tangible Book Value per Share
- -
9.51
9.83
-16.05
-14.76
-13.21
-11.52
-12.36
Basic Weighted Avg Shares
57
57
57
57
57
58
58
59
Sales/Revenue/Turnover
1,109
1,086
1,165
1,130
1,121
1,123
1,080
1,019
Operating Margin (%)
45.27
44.82
42.22
32.63
19.99
25.38
27.43
24.33
Depreciation Expense
36
38
38
32
33
36
41
44
Net Income, GAAP
432
428
415
224
70
78
95
88
Effective Tax Rate (%)
13.6
11.98
16.19
12.86
33.4
- -
30.01
30
Profit Margin (%)
38.95
39.39
35.6
19.8
6.28
6.97
8.83
8.59
Working Capital
- -
98
128
364
396
387
370
285
LT Debt
- -
- -
- -
1,631
1,625
1,596
1,417
1,343
Total Equity
- -
572
594
-891
-822
-739
-651
-613
Return on Invested Capital (%)
- -
149.73
70.71
46.79
18.33
- -
24.69
20.25
Return on Capital (%)
- -
149.51
71.13
39.19
18.06
- -
20.68
18.21
Return on Common Equity (%)
- -
149.51
71.13
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
13
13
143
LT Borrowings
1,353
1,317
1,316
LT Finance Leases
28
28
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
59
57
Market Capitalization
703
524
185

Working Capital

FRC

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
620
608
705
Cash, Cash Equivalents & STI
201
185
215
Accounts Receivable, Net
159
147
182
Inventories
182
193
214
Total Current Liabilities
235
247
420
Payables & Accruals
222
234
277
ST Debt
13
13
143
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-55.17%
-11.87%
Free Cash Flow
- -
57.58%
436.97%
Net Income, GAAP
- -
-16.91%
21.84%
Sales/Revenue/Turnover
- -
-0.02%
-3.8%
Total Cash Common Dividend
- -
- -
1.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
277
287
272
286
1,123
2025
262
259
296
264
1,080
2026
261
222
272
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
0.5
0.25
0.25
1.36
2025
- -
0.4
0.78
0.45
1.64
2026
0.75
-0.07
0.36
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.15
0.15
0.15
0.6
2025
0.15
0.15
0.15
0.15
0.6
2026
0.15
0.15
0.01
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Devdatt Kurdikar
Full Time Employees
1,850
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
300 Kimball Drive Parsippany NJ United States of America 07054
IPO Date
Mar 22, 2022
CIK
0001872789
Website
embecta.com
Similar Companies
COLTENE Holding AG (CLTN.SW)
Embecta Corp. (EMBC)
Becton, Dickinson and Company (BDXB)
EssilorLuxottica S.A. (ESLOY)
Shanghai Kindly Medical Instruments Co., Ltd. (1501.HK)
Nipro Corporation (NPRRF)
Business
Embecta Corp. (Nasdaq: EMBC), a global medical device company focused on diabetes care solutions, designs, manufactures and markets insulin delivery products including pen needles, syringes, safety injection devices; digital applications such as the BD Diabetes Care app for patient management; and innovative technologies like patch pump systems, primarily sold to wholesalers, distributors, pharmacies and healthcare providers serving people living with diabetes in over 100 countries. Founded in 1924 and headquartered in Parsippany, New Jersey, the company operates manufacturing facilities in the United States, Ireland and China while maintaining nearly 100 years of expertise spun off from Becton Dickinson in April 2022. Embecta recently strengthened its leadership through a long-range financial plan for fiscal 2025-2028 targeting flat constant currency revenue growth, adjusted operating margins of 28-30% and $600 million in cumulative free cash flow; expanded partnerships with over 30 generic GLP-1 companies for pen needle co-packaging and supply including purchase orders and regulatory submissions; committed to expanded humanitarian efforts with Direct Relief through 2026 for pen needle and syringe access following a July 2025 Texas grant; and reported fiscal 2025 fourth quarter results with Q3 revenue near $296 million amid ongoing transition to growth and diversification including GLP-1 opportunities and debt reduction.

Company News

Company News APIChatGPT

  • defenseworld.net

    Reviewing Rockwell Medical (NASDAQ:RMTI) & Embecta (NASDAQ:EMBC)

  • globenewswire.com

    EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

  • globenewswire.com

    EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

  • globenewswire.com

    embecta to Participate in Investor Events

  • newsfilecorp.com

    EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

  • seekingalpha.com

    The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

  • newsfilecorp.com

    EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

  • prnewswire.com

    EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop

  • businesswire.com

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

  • gurufocus.com

    EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

  • prnewswire.com

    EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

  • globenewswire.com

    Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm

  • globenewswire.com

    EMBC Court News: Embecta Securities Fraud Class Action Filed After Insulin Pen Issues and 57% Stock Drop – Contact BFA Law Before August 17

  • prnewswire.com

    EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

  • prnewswire.com

    Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC

  • globenewswire.com

    EMBC DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action – EMBC

  • newsfilecorp.com

    EMBC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

  • newsfilecorp.com

    EMBC FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Embecta Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - EMBC

  • gurufocus.com

    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026

  • prnewswire.com

    INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026